MaaT Pharma (MAAT) KOL Event summary

Introduction and agenda

• The event focused on MaaT013's development and clinical data for GVHD, featuring presentations from leading KOLs and a Q&A session.

• The agenda included company introduction, KOL presentations, early access program results, unmet need, and future plans.

KOL background and credentials

• Professor Mohammad Mohty is a globally recognized expert in GVHD and HSCT, with over 1,000 peer-reviewed publications.

• Dr. Monzr Al-Malki is the director of blood and marrow transplant at City of Hope and the first to treat a US patient with MaaT013.

• Featured speakers included Prof. Mohamad Mohty, Dr. Monzr M. Al Malki, and Hervé Affagard (Co-Founder & CEO).

Market insights and analysis

• Acute GVHD affects about 12,000 patients annually in the US and Europe, with high mortality in steroid- and ruxolitinib-refractory cases.

• Current standard of care is limited, with only ruxolitinib approved for second-line and no FDA-approved options for third-line.

• MaaT013 is the most advanced product in third-line, with a pivotal Phase 3 trial ongoing and significant market potential estimated at €250m in 3L alone.

• Revenue is currently generated in France, with €2.3m in the first nine months of 2024 and global expansion underway.

• There is a significant unmet need for effective third-line therapies, especially for GI-involved GVHD.